Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming
Authors:
- Sandrine NugterenSNSandrine Nugteren
- Beatriz CaladoBCBeatriz Calado
- Ytje Simons-OosterhuisYSYtje Simons-Oosterhuis
- Willem K. SmitsWSWillem K. Smits
- Renz C.W. KlombergRKRenz C.W. Klomberg
- Bastiaan TukBTBastiaan Tuk
- Mohammed CharroutMCMohammed Charrout
- Dicky J. Lindenbergh-KortleveDLDicky J. Lindenbergh-Kortleve
- Michail DoukasMDMichail Doukas
- Mathijs A. SandersMSMathijs A. Sanders
- Gregory van BeekGBGregory van Beek
Open Access
- 26 February 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (8)
Abstract
Heterogeneity in disease severity and treatment response in inflammatory bowel disease (IBD) likely evolves from individual differences in host-microbiota-immune interactions. Histological evaluation of intestinal biopsies is central to diagnosis, but histological parameters that define underlying immune mechanisms are limited. We investigated histological features that distinguish individual patient immune profiles in therapy-naive pediatric IBD patients (age 6–18 years) using biopsy immunohistochemistry and transcriptomics and plasma proteomics across two cohorts. High colonic epithelial expression of secretory leukocyte protease inhibitor (SLPI), a microbiota-induced regulator of epithelial function, occurred in IBD patients with high clinical disease activity and more severe endoscopic and microscopic disease activity. SLPI expression was related to increased neutrophil infiltration, transcriptomic signatures of activation, and genes known to associate with therapeutic resistance. High SLPI colocalized with high densities of IL-17–secreting cells and was associated with high plasma concentrations of Th17-related immune proteins. Additionally, patients with high intestinal SLPI had an intrinsically different immunotype, in which circulating neutrophils exhibited altered transcription of genes involved in neutrophil granule formation, phagocytosis, oxidative phosphorylation, and interferon signaling. Thus, high colonic SLPI expression at diagnosis associates with severe IBD, increased IL-17A–neutrophil pathway responses, and altered transcriptomic wiring of circulating neutrophils.Keywords
Funding Information
- Maag Lever Darm Stichting (Focus Project 15-17)
- European Commission Horizon 2020 (PIBD-SETQ grant number 668 023)
- Stichting Dalijn (IBD bij Kinderen)
- Dutch Sophia Foundation (grant number 21-45)
- Top Sector Life Sciences & Health and Samenwerkende Gezondheidsfondsen (the collaborative TIMID project [grant number LSHM18057-SGF])
- European Comission Horizon 2020 / Marie Skłodowska-Curie (955332)
This publication has 65 references indexed in Scilit:
- Endogenous secretory leukocyte protease inhibitor inhibits microbial‐induced monocyte activationEuropean Journal of Immunology, 2022
- Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2021
- Airway Microbiota-Host Interactions Regulate Secretory Leukocyte Protease Inhibitor Levels and Influence Allergic Airway InflammationCell Reports, 2020
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Ward’s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward’s Criterion?Journal of Classification, 2014
- Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versionsInflammatory Bowel Diseases, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Antileukoprotease in Human Skin: An Antibiotic Peptide Constitutively Produced by KeratinocytesBiochemical and Biophysical Research Communications, 1998
- Localization of immunoreactive secretory leukocyte protease inhibitor (SLPI) in intestinal mucosaJournal of Gastroenterology, 1996
- Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucinGastroenterology, 1994